Actively Recruiting
Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
Led by The First Affiliated Hospital of Zhengzhou University · Updated on 2025-06-12
208
Participants Needed
1
Research Sites
158 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Esophageal squamous cell cancer (ESCC) has a high incidence in China. Although the fast development of immune check point inhibitors (ICIs), the rate of pCR is limited with the mode of ICIs combined with neoadjuvant radiochemotherapy. The rate of pCR under ICIs combined with neoadjuvant radiochemotherapy was reported around 50%, which means more than half of those patients could not obtain pCR in reality. In order to explore a more effective mode of neoadjuvant therapy for ESCC, we designed this study to evaluate the effect of PD-1/CTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy in local advanced ESCC.
CONDITIONS
Official Title
Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with esophageal squamous cell cancer
- Staged with cT1N+M0 or cT2-3N0-3M0
- No previous cancer-related treatment
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Expected survival longer than 6 months
- Intended to receive neoadjuvant therapy before surgery
- Adequate organ function
You will not qualify if you...
- Diagnosed with other types of cancer within the past five years
- Have a tendency to bleed
- Have received any cancer-related therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450000
Actively Recruiting
Research Team
F
Fuwei Wang
CONTACT
X
Xiangbo Wan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here